Citations 2
NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022
Saad, Ayman , Loren, Alison W. , Bolaños‐Meade, Javier , Chen, George , Couriel, Daniel R. , Stasi, Antonio Di , El‐Jawahri, Areej , Elmariah, Hany , Gundabolu, Krishna , Gutman, Jonathan A. , Ho, Vincent T. , Hoeg, Rasmus T. , Horwitz, Mitchell E. , Hsu, Joe L. , Dabaja, Mohamed Kharfan, Magenau, John, Martin, Thomas , Moreira, Jonathan , Nakamura, Ryotaro , Ninos, Cameron , Oliai, Caspian , Patel, Seema M., Randolph, Brion, Tzachanis, Dimitrios , Varshavsky‐Yanovsky, Asya, Vusirikala, Madhuri , Algieri, Frankie, Pluchino, Lenora A. , Kharfan Dabaja, Mohamed, Saad, Ayman , Elmariah, Hany , Farag, Sherif Shafik , Kassim, Adetola A , Mielcarek, Marco B. , Nieto, Yago , Oliai, Caspian H , Schroeder, Mark A.
Journal of the National Comprehensive Cancer Network | February 15, 2023 | Volume: 21 | Issue: 2 | Pages: 108-115
The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease—a major complication of allogeneic HCT—to enable the patient and clinician to assess management options in the context of an individual patient’s condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.
Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Saad, Ayman , Anand, Sarah , Bookout, Ryan, Couriel, Daniel R. , Stasi, Antonio Di , El‐Jawahri, Areej , Gutman, Jonathan A. , Ho, Vincent T. , Horwitz, Mitchell E. , Hsu, Joe L. , Dabaja, Mohamed Kharfan, Loren, Alison W. , MSCE, Meade, Javier Bolaños, Moreira, Jonathan , Nakamura, Ryotaro , Roddy, Julianna, Satyanarayana, Gowri, Tan, Carlyn , Tzachanis, Dimitrios , Burns, Jennifer L. , Pluchino, Lenora A. , Saad, Ayman , Lima, Marcos de , Bhatt, Vijaya Raj , Chen, George T , Giralt, Sergio , Juckett, Mark , MSCE, Mielcarek, Marco B. , Nieto, Yago , Schroeder, Mark A.
Journal of the National Comprehensive Cancer Network | May 7, 2020 | Volume: 18 | Issue: 5 | Pages: 599-634
Hematopoietic cell transplantation (HCT) involves the infusion of hematopoietic progenitor cells into patients with hematologic disorders with the goal of re-establishing normal hematopoietic and immune function. HCT is classified as autologous or allogeneic based on the origin of hematopoietic cells. Autologous HCT uses the patient’s own cells while allogeneic HCT uses hematopoietic cells from a human leukocyte antigen-compatible donor. Allogeneic HCT is a potentially curative treatment option for patients with certain types of hematologic malignancies, and autologous HCT is primarily used to support patients undergoing high-dose chemotherapy. Advances in HCT methods and supportive care in recent decades have led to improved survival after HCT; however, disease relapse and posttransplant complications still commonly occur in both autologous and allogeneic HCT recipients. Allogeneic HCT recipients may also develop acute and/or chronic graft-versus-host disease (GVHD), which results in immune-mediated cellular injury of several organs. The NCCN Guidelines for Hematopoietic Cell Transplantation focus on recommendations for pretransplant recipient evaluation and the management of GVHD in adult patients with malignant disease.